Reardon, D. A., Nayak, L., Peters, K. B., Clarke, J. L., Jordan, J. T., De Groot, J. F., … Wen, P. Y. (2018). Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. In Journal of Clinical Oncology (Vol. 36, pp. 2006–2006). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.15_suppl.2006

Reardon, David A., Lakshmi Nayak, Katherine B. Peters, Jennifer Leigh Clarke, Justin T. Jordan, John Frederick De Groot, Phioanh Leia Nghiemphu, et al. “Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.” In Journal of Clinical Oncology, 36:2006–2006. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.15_suppl.2006.

Reardon DA, Nayak L, Peters KB, Clarke JL, Jordan JT, De Groot JF, et al. Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 2006–2006.

Reardon, David A., et al. “Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients.” Journal of Clinical Oncology, vol. 36, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 2006–2006. Crossref, doi:10.1200/jco.2018.36.15_suppl.2006.

Reardon DA, Nayak L, Peters KB, Clarke JL, Jordan JT, De Groot JF, Nghiemphu PL, Kaley TJ, Colman H, Gaffey SC, Caruso V, Bednarek Debruyne M, Bhavsar C, Molinaro AM, Smith T, Severgnini M, Wen PY. Phase II study of pembrolizumab or pembrolizumab plus bevacizumab for recurrent glioblastoma (rGBM) patients. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 2006–2006.